SESN2 and hepatocellular carcinoma: Collectively, we revealed that SESN2 deficiency diminished the activation of AKT and AMPK signaling after sorafenib treatment, probably accounting for the inhibition of cell viability, the increase of cell apoptosis and concurrent reduction of ATP levels in HCC cells.